(Q34164735)

31 July 2017

A review on various targeted anticancer therapies (English)

1 reference

31 July 2017

5

Uwe Himmelreich

1 reference

31 July 2017

Junjie Li

1

1 reference

31 July 2017

Feng Chen

2

1 reference

31 July 2017

Marlein Miranda Cona

3

1 reference

31 July 2017

Yuanbo Feng

4

1 reference

31 July 2017

Raymond Oyen

6

1 reference

31 July 2017

Alfons Verbruggen

7

1 reference

31 July 2017

Yicheng Ni

8

1 reference

31 July 2017

15 February 2012

1 reference

31 July 2017

1 reference

31 July 2017

7

1 reference

31 July 2017

1

1 reference

31 July 2017

69-85

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-012-0212-2

31 July 2017

0 references

cites work

The globalisation of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Cell cycle control as a basis for cancer chemoprevention through dietary agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Models for prevention and treatment of cancer: problems vs promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Advances in the treatment for haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Targeting targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

A dual-targeting anticancer approach: soil and seed principle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

A pharmacophore map of small molecule protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Targeting protein kinases in cancer therapy: a success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Current and future directions in mammalian target of rapamycin inhibitors development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Part I: Milestones in personalised medicine--imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Monoclonal antibody therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

21 January 2018

Anticancer antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Biologic and therapeutic role of HER2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Adjuvant trastuzumab therapy for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

The role of HER2 in cancer therapy and targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Understanding rituximab function and resistance: implications for tailored therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Angiogenesis: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Vascular targeted therapies in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Taking down tumors: vascular disrupting agents entering clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

VEGF receptor signaling in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Vascular disrupting agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Imaging in targeted delivery of therapy to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

In vivo molecular targeted radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Radiolabeled peptides in oncology: role in diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Targeted therapy in nuclear medicine--current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Necrosis avid contrast agents: functional similarity versus structural diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Targeted cancer therapy: conferring specificity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Antibody-directed therapies for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Toxicities of targeted therapy and their management in kidney cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Strategies to improve radiotherapy with targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0212-2

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates

21 January 2018

1 reference

12 December 2020

Targeted therapies for cancer 2004.

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

Targeted therapy in haematological malignancies

1 reference

12 December 2020

The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

1 reference

12 December 2020

Differentiation and definition of vascular-targeted therapies.

1 reference

12 December 2020

Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings

1 reference

12 December 2020

Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

1 reference

12 December 2020

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Exploration of the mechanism underlying the tumor necrosis avidity of hypericin

1 reference

12 December 2020

Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs

1 reference

12 December 2020

Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience

1 reference

12 December 2020

Monoclonal antibodies and therapy of human cancers

1 reference

12 December 2020

Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody

1 reference

12 December 2020

Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent

1 reference

12 December 2020

Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer.

1 reference

12 December 2020

Nuclear localizing sequences: an innovative way to improve targeted radiotherapy.

1 reference

12 December 2020

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer

1 reference

12 December 2020

Part II: Milestones in personalised medicine--trastuzumab

1 reference

12 December 2020

Rituximab in the treatment of non-Hodgkin's lymphoma

1 reference

12 December 2020

Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects

1 reference

12 December 2020

Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model.

1 reference

12 December 2020

Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

1 reference

12 December 2020

Tumor hypoxia in cancer therapy

1 reference

12 December 2020

Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?

1 reference

12 December 2020

10.1007/S11523-012-0212-2

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference